Heart failure with preserved ejection fraction (HFpEF), perfusion and metabolism - Heart failure with preserved ejection fraction, early diagnosis

Academisch Medisch Centrum0 sites48 target enrollmentTBD

Overview

Trial is onging in other countries

Registry

who.int

Start Date

TBD

End Date

November 19, 2019

Last Updated

last year

Study Type

Observational invasive

Sponsor

•1\. All patients
•\* Age \> 50
•\* Estimated glomerular filtration reserve (eGFR) \>30 ml/min
•\* Body weight\<130kg ;1\.1\. HFpEF group
•\*Diagnosis of HFpEF, requires three conditions to be satisfied, as stated in the ESC guidelines:
•(1\) symptoms or signs of heart failure
•(2\) normal or only mildly reduced LV ejection fraction in a non\-dilated LV (LVEF\>\<\= 50%)
•(3\) relevant structural heart disease (LV hypertrophy/LA enlargement) and/or diastolic dysfunction.
•\*Current BP \< 160/90
•\*Estimated glomerular filtration reserve (eGFR) \>30 ml/min

•A potential subject who meets any of the following criteria will be excluded from participation in this study:;\- Age \< 50 years
•\- Life expectancy of \<1 year (malignancy etc.)
•\- Contraindication for CMR
•\* ODIN protocol:
•\* \*Uitvoering van MRI onderzoek bij patiënten met een cardiaal implanteerbaar elektronisch device (CIED), waaronder een pacemaker en ICD\*
•\* ODIN protocol:
•\* \*Voorbereiding klinische patiënten voor MRI onderzoek\*
•\* Metallic implant (vascularclip, neuro\-stimulator, cochlearimplant)
•\* Pacemaker or implantable cardiac defibrillator(ICD)
•\* Claustrophobia